Age: 80.0
Sex: M
Vaccine: UNK, UNK, VARZOS
Symptoms: Blindness unilateral, Gingival swelling, Headache, Magnetic resonance imaging head normal, Uveitis
Clinical narrative: Vision had further deteriorated in left eye; Improvement in pressure and inflammation; Eye pressure was "off the charts, borderline; Loss of eyesight, increased loss of vision, likely need surgery, just about blind; Shingles in left eye, became "just about blind"; Shooting pain between temple and forehead left side; Headaches on the left side; Right eye has some blurriness, eyesight blurry left eye; Shingles across nose, bridge of nose, under left eye; This serious case was reported by a consumer via call center representative and described the occurrence of loss of vision in a 80-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 25-JAN-2023, the patient received the 1st dose of Shingrix (intramuscular). On 28-JAN-2023, 3 days after receiving Shingrix, the patient experienced loss of vision (Verbatim: Loss of eyesight, increased loss of vision, likely need surgery, just about blind) (serious criteria GSK medically significant), ophthalmic herpes zoster (Verbatim: Shingles in left eye, became "just about blind") (serious criteria GSK medically significant), shooting pain (Verbatim: Shooting pain between temple and forehead left side), headache (Verbatim: Headaches on the left side), blurred vision (Verbatim: Right eye has some blurriness, eyesight blurry left eye) and shingles (Verbatim: Shingles across nose, bridge of nose, under left eye). On 13-FEB-2023, the patient experienced increased intraocular pressure (Verbatim: Eye pressure was "off the charts, borderline). On an unknown date, the patient experienced deterioration of visual acuity (Verbatim: Vision had further deteriorated in left eye) and eye inflammation (Verbatim: Improvement in pressure and inflammation). The patient was treated with prednisolone acetate, levobunolol and brimonidine. The outcome of the loss of vision, blurred vision and deterioration of visual acuity were not resolved and the outcome of the ophthalmic herpes zoster, shooting pain, headache and shingles were unknown and the outcome of the increased intraocular pressure and eye inflammation were resolving.   It was unknown if the reporter considered the loss of vision, ophthalmic herpes zoster, shooting pain, headache, blurred vision, shingles, increased intraocular pressure, deterioration of visual acuity and eye inflammation to be related to Shingrix.     It was unknown if the company considered the loss of vision, ophthalmic herpes zoster, shooting pain, headache, blurred vision, shingles, increased intraocular pressure, deterioration of visual acuity and eye inflammation to be related to Shingrix.   Additional Information: GSK Receipt Date:  The patient reported this case for himself. The patient reported that he received Shingrix vaccine, three days later he began experiencing a loss of eyesight, shooting pain between left temple and forehead and headaches on the left side. He states that it is mostly the left eye affected, but the right eye has some blurriness. On February 6, 2023 the patient experienced an increased loss of vision. On February 13, 2023, he was diagnosed with shingles in his left eye, across his nose and bridge of nose, and under his left eye. He became just about blind at this point. He began seeing a series of doctors and Prednisol One Acetate 0.1%, Levobunolol 0.5%, and Brimonidine 0.2% was prescribed. At this time, his eye pressure was off the charts. His general practitioner told him he didn't believe the shot caused it, but later agreed with the local ophthalmologist that the Shingrix vaccine triggered it.  On February 15, 2023, he saw his general practitioner and the shingles lesions were drying. On February 28, 2023, he saw a retinal specialist who stated no damage was done to his retina. On March 6, 2023, his visit with his ophthalmologist revealed that his vision had further deteriorated in his left eye. On March 13, 2023, he saw a cornea specialist who made adjustments to his medications. On March 17, 2023, he saw his local Ophthalmologist who reported his eye pressure was borderline. On Marcy 27, 2023, he saw his cornea specialist again, who reported an improvement in pressure and inflammation. No improvement in vision. He states that he can only see the large letter E on the eye chart. The cornea specialist told him he will likely need surgery, but he does not know any details about the surgery. He was going to return to physician on May 2, 2023 for further evaluation. This case is a potential legal case. Patient was seeking compensation for his suffering. He stated he don't want to sue anyone. The reporter consented to follow-up.